CBLL
What one share of CeriBell holds
Electromedical and Electrotherapeutic Apparatus
We are a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting.
CeriBell’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.72 |
|---|---|
| Profit | −$1.76 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.46 |
| Cash and investments | $3.38 |
| Debt | $0.52 |
| Book value | $3.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $8.53 | −$5.56 | $0.19 | −$5.68 | — | −$20.67 |
| 2024 | $5.48 | −$3.39 | $0.11 | −$3.04 | — | — |
| 2025 | $2.44 | −$1.46 | $0.02 | −$1.14 | — | $4.14 |